9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
232 articles with GlycoMimetics, Inc.
GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapy
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone
GlycoMimetics, Inc. announced that senior management will present corporate updates at two upcoming investor conferences in April.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston, on Tuesday, March 12, 2019, at 9:20 a.m. ET.
Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia (AML) at sites in U.S., Europe, Canada and Australia
Current Board Member Tim Pearson to become Board Chair effective at the close of the company’s annual meeting on May 17, 2019
GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET.
GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
GlycoMimetics, Inc. shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist.
Data in relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) patients underscore clinical opportunities across multiple outcomes measures and subgroups
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT.
Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc.
GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites
Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment
New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET.
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows
Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia